CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC boosted its position in shares of CG Oncology, Inc. (NASDAQ:CGON) by 17.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 230,390 shares of the company’s stock after acquiring an additional 34,131 shares during the period. ArrowMark Colorado Holdings LLC’s holdings in CG Oncology were worth $8,693,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Amalgamated Bank increased its holdings in CG Oncology by 107.6% in the third quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock valued at $61,000 after buying an additional 840 shares during the last quarter. California State Teachers Retirement System acquired a new stake in CG Oncology during the 1st quarter worth $103,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CG Oncology during the 3rd quarter worth $241,000. Profund Advisors LLC purchased a new position in CG Oncology during the 2nd quarter worth $300,000. Finally, SG Americas Securities LLC acquired a new position in CG Oncology in the third quarter valued at $664,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

CG Oncology Trading Up 2.9 %

CGON opened at $35.77 on Tuesday. The firm’s fifty day moving average is $35.94 and its two-hundred day moving average is $34.81. CG Oncology, Inc. has a twelve month low of $25.77 and a twelve month high of $50.23.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, equities analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on CGON shares. Roth Mkm started coverage on CG Oncology in a report on Tuesday, August 27th. They set a “buy” rating and a $65.00 price objective on the stock. UBS Group began coverage on shares of CG Oncology in a report on Thursday, October 24th. They issued a “buy” rating and a $60.00 price target on the stock. Royal Bank of Canada started coverage on CG Oncology in a research note on Monday, September 23rd. They set an “outperform” rating and a $66.00 price objective on the stock. Bank of America restated a “buy” rating and issued a $65.00 price target on shares of CG Oncology in a research note on Tuesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of CG Oncology in a report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, CG Oncology has an average rating of “Buy” and an average target price of $63.88.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.